Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
May 15, 2024 at 06:20 am
Share
Nexien BioPharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported net loss was USD 0.053163 million compared to USD 0.079853 million a year ago. Basic loss per share from continuing operations was USD 0.001 compared to USD 0.001 a year ago. Diluted loss per share from continuing operations was USD 0.001 compared to USD 0.001 a year ago.
For the nine months, net loss was USD 0.152599 million compared to USD 0.268319 million a year ago. Basic loss per share from continuing operations was USD 0.002 compared to USD 0.004 a year ago. Diluted loss per share from continuing operations was USD 0.002 compared to USD 0.004 a year ago.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
